Development of a preclinical testing platform for clinically relevant therapy for Dravet syndrome
This research lays the groundwork for exploring effective add-on compounds to clobazam and valproic acid in treating Dravet syndrome. The study further highlights the utility of the Scn1a<sup>A1783V/WT</sup> mice in discovering therapies for Dravet syndrome-associated pharmacoresistant seizures.
Authors
- Christopher A. Reilly (ORCID: https://orcid.org/0000-0002-5006-1982)
- Jeffrey A. Mensah (ORCID: https://orcid.org/0000-0001-7026-9329)
- Cameron S. Metcalf (ORCID: https://orcid.org/0000-0002-1510-0405)
- Joseph E. Rower (ORCID: https://orcid.org/0000-0003-3629-7902)
- Karen S. Wilcox (ORCID: https://orcid.org/0000-0003-2660-8826)
- Kyle E. Thomson (ORCID: https://orcid.org/0000-0003-2345-4526)
- Tia Freeman
- Jennifer L. Huff
Institutions
- University of Utah (US)
Publication Details
- Journal
- Epilepsia
- Published
- 2025-06-30
- DOI
- https://doi.org/10.1111/epi.18516
- Citations
- 2
- Primary Topic
- Epilepsy research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.94
Funders
- National Institute of Neurological Disorders and Stroke